Sign up to get the free monthly PDSA E-News delivered directly to your inbox. Provide us with your email address to get first-hand news, alerts and periodic mailings about events and ways to make an impact from the premier resource for ITP and other platelet disorders.
Choose the issue you would like to read below:
Living with ITP can be frightening for patients and their families and these worries have been worsened in the setting of COVID19. One of the factors that makes ITP so challenging is that it is very hard to predict if and when bleeding may occur, and if bleeding might be severe, even life-threatening. This uncertainty makes it difficult to decide which medication to select, and when and how to deploy it to treat patients. The following two articles discuss risk factors that could help in predicting the development of severe bleeds.
- Severe Immune Thrombocytopenia Complicated by Intracerebral Haemorrhage Associated with Coronavirus Infection: A Case Report and Literature Review
- Immune Thrombocytopenia in Very Elderly Patients: Particularities in Presentation and Management. Results from the Multicenter Prospective Carmen-France Registry
In this issue of the e-news, we report on a few additional abstracts that were presented at the December (2019) American Society of Hematology meeting, in Orlando, Florida. The ASH abstract numbers are shown in parentheses. You can search on the number and read the complete abstract at: https://ashpublications.org/blood/issue/134/Supplement_1
- Racial Variation in ITP Prevalence and Rate of Chronic Disease Suggests Biological Differences (130418)
- High-Dose Dexamethasone (HD-DXM) Plus Oseltamivir vs High-Dose Dexamethasone for Treatment of Adult Primary Immune Thrombocytopenia: interim analysis of a prospective, multi-center, randomized controlled trial (121825)
Innovative ITP Research from the 2019 American Society of Hematology (ASH) Annual Meeting
This year’s 2019 ASH meeting, held December 7-10 in Orlando (Florida), attracted over 30,000 clinicians, scientists, pharmaceutical company personnel and even investment analysts worldwide to share ground-breaking research in the field of hematology. The conference included the annual ITP breakfast meeting, coordinated by PDSA and four of PDSA’s Medical Advisors, Dr. James Bussel, Dr. Nichola Cooper, Dr. Michele Lambert and Dr. John Semple. Thirteen hematology experts were invited to present their leading-edge ITP research. In this e-news issue, we report on experimental therapies for ITP for which updates on or new clinical trials were presented.